Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00069799 | Breast | Precancer | response to oxidative stress | 70/1080 | 446/18723 | 1.59e-14 | 4.26e-12 | 70 |
GO:00621979 | Breast | Precancer | cellular response to chemical stress | 51/1080 | 337/18723 | 2.40e-10 | 2.34e-08 | 51 |
GO:00160329 | Breast | Precancer | viral process | 58/1080 | 415/18723 | 3.42e-10 | 3.16e-08 | 58 |
GO:00003029 | Breast | Precancer | response to reactive oxygen species | 38/1080 | 222/18723 | 1.47e-09 | 1.23e-07 | 38 |
GO:00709979 | Breast | Precancer | neuron death | 50/1080 | 361/18723 | 7.75e-09 | 5.70e-07 | 50 |
GO:00514029 | Breast | Precancer | neuron apoptotic process | 38/1080 | 246/18723 | 2.68e-08 | 1.75e-06 | 38 |
GO:00345999 | Breast | Precancer | cellular response to oxidative stress | 42/1080 | 288/18723 | 2.78e-08 | 1.79e-06 | 42 |
GO:00444039 | Breast | Precancer | biological process involved in symbiotic interaction | 42/1080 | 290/18723 | 3.40e-08 | 2.11e-06 | 42 |
GO:00086378 | Breast | Precancer | apoptotic mitochondrial changes | 23/1080 | 107/18723 | 3.44e-08 | 2.12e-06 | 23 |
GO:00349769 | Breast | Precancer | response to endoplasmic reticulum stress | 38/1080 | 256/18723 | 7.89e-08 | 4.60e-06 | 38 |
GO:00425429 | Breast | Precancer | response to hydrogen peroxide | 26/1080 | 146/18723 | 2.52e-07 | 1.26e-05 | 26 |
GO:00100389 | Breast | Precancer | response to metal ion | 47/1080 | 373/18723 | 3.88e-07 | 1.79e-05 | 47 |
GO:00511019 | Breast | Precancer | regulation of DNA binding | 22/1080 | 118/18723 | 9.28e-07 | 3.71e-05 | 22 |
GO:19012149 | Breast | Precancer | regulation of neuron death | 41/1080 | 319/18723 | 1.27e-06 | 4.80e-05 | 41 |
GO:00435237 | Breast | Precancer | regulation of neuron apoptotic process | 31/1080 | 212/18723 | 1.69e-06 | 6.08e-05 | 31 |
GO:00075653 | Breast | Precancer | female pregnancy | 29/1080 | 193/18723 | 2.07e-06 | 7.31e-05 | 29 |
GO:00510989 | Breast | Precancer | regulation of binding | 44/1080 | 363/18723 | 2.59e-06 | 8.65e-05 | 44 |
GO:00447063 | Breast | Precancer | multi-multicellular organism process | 31/1080 | 220/18723 | 3.73e-06 | 1.19e-04 | 31 |
GO:00300999 | Breast | Precancer | myeloid cell differentiation | 45/1080 | 381/18723 | 4.00e-06 | 1.25e-04 | 45 |
GO:00018367 | Breast | Precancer | release of cytochrome c from mitochondria | 14/1080 | 59/18723 | 4.80e-06 | 1.47e-04 | 14 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513073 | Oral cavity | NEOLP | Pathogenic Escherichia coli infection | 55/1112 | 197/8465 | 2.04e-08 | 4.32e-07 | 2.72e-07 | 55 |
hsa0520371 | Oral cavity | NEOLP | Viral carcinogenesis | 56/1112 | 204/8465 | 2.90e-08 | 5.34e-07 | 3.36e-07 | 56 |
hsa0513173 | Oral cavity | NEOLP | Shigellosis | 62/1112 | 247/8465 | 1.93e-07 | 2.79e-06 | 1.75e-06 | 62 |
hsa0413772 | Oral cavity | NEOLP | Mitophagy - animal | 26/1112 | 72/8465 | 5.95e-07 | 7.88e-06 | 4.95e-06 | 26 |
hsa0493371 | Oral cavity | NEOLP | AGE-RAGE signaling pathway in diabetic complications | 32/1112 | 100/8465 | 7.36e-07 | 9.10e-06 | 5.72e-06 | 32 |
hsa0541873 | Oral cavity | NEOLP | Fluid shear stress and atherosclerosis | 40/1112 | 139/8465 | 7.44e-07 | 9.10e-06 | 5.72e-06 | 40 |
hsa0516971 | Oral cavity | NEOLP | Epstein-Barr virus infection | 51/1112 | 202/8465 | 1.96e-06 | 2.01e-05 | 1.27e-05 | 51 |
hsa046257 | Oral cavity | NEOLP | C-type lectin receptor signaling pathway | 30/1112 | 104/8465 | 1.69e-05 | 1.45e-04 | 9.12e-05 | 30 |
hsa0517071 | Oral cavity | NEOLP | Human immunodeficiency virus 1 infection | 49/1112 | 212/8465 | 4.05e-05 | 3.22e-04 | 2.02e-04 | 49 |
hsa0516672 | Oral cavity | NEOLP | Human T-cell leukemia virus 1 infection | 50/1112 | 222/8465 | 6.91e-05 | 5.23e-04 | 3.29e-04 | 50 |
hsa051627 | Oral cavity | NEOLP | Measles | 35/1112 | 139/8465 | 8.30e-05 | 6.14e-04 | 3.86e-04 | 35 |
hsa0472271 | Oral cavity | NEOLP | Neurotrophin signaling pathway | 31/1112 | 119/8465 | 1.06e-04 | 7.67e-04 | 4.82e-04 | 31 |
hsa0521171 | Oral cavity | NEOLP | Renal cell carcinoma | 21/1112 | 69/8465 | 1.32e-04 | 9.32e-04 | 5.86e-04 | 21 |
hsa0541773 | Oral cavity | NEOLP | Lipid and atherosclerosis | 47/1112 | 215/8465 | 2.39e-04 | 1.61e-03 | 1.01e-03 | 47 |
hsa0453055 | Oral cavity | NEOLP | Tight junction | 39/1112 | 169/8465 | 2.50e-04 | 1.62e-03 | 1.02e-03 | 39 |
hsa0513571 | Oral cavity | NEOLP | Yersinia infection | 33/1112 | 137/8465 | 3.20e-04 | 2.00e-03 | 1.26e-03 | 33 |
hsa043805 | Oral cavity | NEOLP | Osteoclast differentiation | 31/1112 | 128/8465 | 4.35e-04 | 2.60e-03 | 1.63e-03 | 31 |
hsa051617 | Oral cavity | NEOLP | Hepatitis B | 37/1112 | 162/8465 | 4.41e-04 | 2.60e-03 | 1.63e-03 | 37 |
hsa046605 | Oral cavity | NEOLP | T cell receptor signaling pathway | 26/1112 | 104/8465 | 7.37e-04 | 3.72e-03 | 2.34e-03 | 26 |
hsa0401051 | Oral cavity | NEOLP | MAPK signaling pathway | 59/1112 | 302/8465 | 9.40e-04 | 4.67e-03 | 2.94e-03 | 59 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
JUN | MLUM | Breast | DCIS | DUSP1,JUNB,MALAT1, etc. | 6.42e-01 | |
JUN | CD4TN | Cervix | CC | HSPA1B,DNAJB1,HSPA1A, etc. | 1.26e-01 | |
JUN | CD8TEFF | Cervix | CC | HSPA1B,DNAJB1,HSPA1A, etc. | 8.34e-02 | |
JUN | TFH | Cervix | CC | HSPA1B,DNAJB1,HSPA1A, etc. | 6.17e-02 | |
JUN | CD8TEXP | Liver | Cirrhotic | HSPA1A,HSPA1B,HSPB1, etc. | 1.35e-01 | |
JUN | CD8TCM | Pancreas | PDAC | DNAJB1,HSPA1B,ID2, etc. | 2.45e-01 | |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3725 | JUN | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TUMOR SUPPRESSOR, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | DIPHENHYDRAMINE HYDROCHLORIDE | DIPHENHYDRAMINE HYDROCHLORIDE | |
3725 | JUN | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TUMOR SUPPRESSOR, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | COLCHICINE | COLCHICINE | |
3725 | JUN | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TUMOR SUPPRESSOR, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | CIPROFIBRATE | CIPROFIBRATE | 16680159 |
3725 | JUN | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TUMOR SUPPRESSOR, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | VINBLASTINE SULFATE | VINBLASTINE SULFATE | |
3725 | JUN | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TUMOR SUPPRESSOR, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | PATULIN | PATULIN | 16680159 |
3725 | JUN | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TUMOR SUPPRESSOR, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | ALPHA-DIFLUOROMETHYLORNITHINE | | 9950818 |
3725 | JUN | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TUMOR SUPPRESSOR, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | METHIMAZOLE | METHIMAZOLE | |
3725 | JUN | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TUMOR SUPPRESSOR, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | DFMO | | 9950818 |
3725 | JUN | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TUMOR SUPPRESSOR, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | 2-MERCAPTOPYRIMIDINE | 2-MERCAPTOPYRIMIDINE | |
3725 | JUN | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TUMOR SUPPRESSOR, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | SODIUM SELENITE | SODIUM SELENITE | |